Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency - PubMed
4 hours ago
- #biparatopic-antibodies
- #IL-23-neutralization
- #antibody-engineering
- Engineered biparatopic antibodies (bpAbs) targeting human IL-23 by combining variable regions of ustekinumab and guselkumab into IgG-like and Fab-IgG formats.
- BpAbs demonstrated picomolar affinities and avidity-driven affinity enhancements, with dual-epitope engagement confirmed via SPR bridging assay.
- Mass photometry showed in trans immune complex formation and stoichiometry-dependent multimerization across bpAb formats.
- Functional neutralization assays and a mechanistic model validated enhanced potency, equivalent to equimolar antibody mixtures, for soluble cytokine targeting.